KRYS Krystal Biotech, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
22:22
Aug 18
Aug 18
Author confirms holding Cytokinetics since 2024 and added at $82.80.
Author confirms holding Cytokinetics since 2024 and added at $82.80, while listing other long ideas and short candidates from a prior post without explicit current positioning.
11:47
Aug 03
Aug 03
Premarket movers show mixed results with Atkore surging on acquisition news.
Premarket movers show mixed results with Atkore surging on acquisition news, Bristol-Myers gaining on takeover interest, and several stocks falling on earnings misses or guidance cuts.
18:42
Jul 29
Jul 29
Speculative M&A thesis linking JNJ to KRYS after plane tracking in Pittsburgh.
Speculative M&A thesis linking JNJ to KRYS after plane tracking in Pittsburgh; author does not commit to a direction.
LOW
17:14
Jul 27
Jul 27
Speculative M&A mention — author identifies KRYS as the sole logical acquisition target for JNJ.
Speculative M&A mention — author identifies KRYS as the sole logical acquisition target for JNJ following a Pittsburgh meeting, citing a potential $10B+ deal size. No personal position disclosed.
MED
15:21
Jul 07
Jul 07
Minervini discloses KRYS as a current open position and one of his best-performing holdings.
Minervini discloses KRYS as a current open position and one of his best-performing holdings in a rotational market environment, suggesting continued constructive tape action.
MED
17:48
Jun 11
Jun 11
Author discloses active long position in KRYS, entered before the market pullback.
Author discloses active long position in KRYS, entered before the market pullback, currently profitable; held within a hedged book outperforming short index exposure.
MED
About KRYS Analyst Coverage
Buzzberg tracks KRYS (Krystal Biotech, Inc. Common Stock) across 3 sources. 2 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (33%). 6 total trade ideas tracked. Latest voices: seedy19tron, zerohedge, Mark Minervini.